Human Pathology
Volume 34, Issue 1 , Pages 74-79 , January 2003

Expression of Fas and FasL in human serous ovarian epithelial tumors

,Accepted 26 September 2002.

References 

  1. Kam PCA, Ferch NI. Apoptosis: Mechanisms and clinical implications (review article). Anaesthesia. 2000;55:1081–1093
  2. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990;40:2353–2362
  3. Hickman JA, Potten CS, Merritt AJ, et al.  Apoptosis and cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1994;345:319–325
  4. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449–1456
  5. Suda T, Takahashi S, Golstein P, et al.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169–1178
  6. Itoh N, Yonehara S, Ishii A, et al.  The polypeptide encoded by cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991;66:233–243
  7. Leithauser F, Dhein J, Mechtersheimer G, et al.  Constitutive and induced expression of APO-1 a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993;69:415–429
  8. Quirk SM, Cowan RG, Joshi S, et al.  Fas antigen-mediated apoptosis in human granulosa/luteal cells. Biol Reprod. 1995;52:279–287
  9. Foghi A, Ravandi A, Teerds KJ, et al.  Fas-induced apoptosis in rat thecal/interstitial cells signals through the sphingomyelin-ceramide pathway. Endocrinology. 1998;139:2041–2047
  10. Quirk SM, Cowan RG, Huber SH. Fas antigen–mediated apoptosis of ovarian surface epithelial cells. Endocrinology. 1997;138:4558–4566
  11. Nagata S. Apoptosis by death factor. Cell. 1997;88:355–365
  12. Peters ME, Scaffidi C, Medema JP, et al.  The death receptors. In:  Kumar S editors. Apoptosis, Problems and Diseases. Heidelberg, Germany: Springer; 1998;
  13. O'Connell J, Bennett MW, O'Sullivan GC, et al.  The Fas counterattack: Cancer as a site of immune privilege. Immunol Today. 1999;20:46–52
  14. O'Connell J, O'Sullivan GC, Collins JK, et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184:1075–1082
  15. O'Connell J, Bennett MW, O'Sullivan GC, et al.  Fas counterattack: The best form of tumor defense?. Nat Med. 1999;5:267–268
  16. Russell P, Farnsworth A. Surgical Pathology of the Ovaries. ed 2. New York, NY: Churchill Livingstone; 1997;
  17. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In:  Scully RE,  Young RH,  Clemente PB editor. Atlas of Tumor Pathology, Third Series. Washington, DC: Armed Forces Institute of Pathology; 1998;
  18. van Haaften-Day C, Russell P, Rugg C, et al.  Flow cytometric and morphological studies of ovarian carcinoma cell lines and xenografts. Cancer Res. 1983;43:3725–3731
  19. van Haaften-Day C, Russell P, Davies S, et al.  An in vitro study of ovarian atypical proliferating (borderline) serous tumors. Int J Gynecol Cancer. 1992;2:41–48
  20. van Haaften-Day C, Russell P, Boyer CM, et al.  Expression of cell regulatory van proteins in ovarian borderline tumors. Cancer. 1996;77:2092–2098
  21. Rudin CM, Thompson CB. Apoptosis and disease: Regulation and clinical relevance of programmed cell death. Ann Rev Med. 1997;48:267–281
  22. Zusman I, Gurevich P, Gurevich E, et al.  The immune system, apoptosis and apoptosis-related proteins in human ovarian tumours (a review). Int J Oncol. 2001;18:965–972
  23. Griffith TS, Brunner T, Fletscher SM, et al.  Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189–1192
  24. Bellgrau D, Gold D, Selawry H, et al.  A role for CD95 ligand in preventing graft rejection. Nature. 1995;377:630–632
  25. Munakata S, Enomoto T, Tsujimoto M, et al.  Expressions of Fas ligand and other apoptosia-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer. 2000;82:1446–1452
  26. Wakahara Y, Nawa A, Okamoto T, et al.  Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Oncology. 1997;54:48–54
  27. Cai Z, Stancou R, Korner M, et al.  Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumour cells. Int J Cancer. 1996;68:535–546
  28. Uslu R, Jewett A, Bonavida B. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-Fas antibody–mediated cytotoxicity and apoptosis. Gynecol Oncol. 1996;62:282–291
  29. Baldwin RL, Tran H, Karlan BY. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. Gynecol Oncol. 1999;74:265–271
  30. Rabinowich H, Reichert TE, Kashii Y, et al.  Lymphocyte apoptosis induced by Fas ligand–expressing ovarian carcinoma cells. J Clin Invest. 1998;101:2579–2588

☆ Address correspondence and reprint requests to Dr. Caroline van Haaften-Day, LCPL Laboratory, Rooseveltstraat 4C, 2321 BM, Leiden, The Netherlands.

PII: S0046-8177(02)29707-5

doi: 10.1053/hupa.2003.7

Human Pathology
Volume 34, Issue 1 , Pages 74-79 , January 2003

Article Tools

* Image Usage & Resolution